TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10051936
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (32 mg)
Study: 2513143
Drug: Flecainide (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (median dose 300 mg/day)
Study: 17095725
Drug: Rho kinase
Normalized name: Rho(D) immune globulin Injection [WinRho]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rho kinase inhibitor, fasudil
Study: 11342364
Drug: CEMP (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEMP (cyclophosphamide, etoposide, mitoxantrone and prednisone) chemotherapy protocol
Study: 11342364
Drug: CEMP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEMP chemotherapy protocol
Study: 7936476
Drug: Lisinopril (10mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10mg, 20mg, 40mg daily)
Study: 7936476
Drug: Captopril (25mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25mg, 50mg, 100mg daily)
Study: 14155162
Drug: Methysergide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide (2 mg, three times a day orally for 5 weeks)
Study: 14155162
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical dosage and duration as methysergide)
Study: 31286645
Drug: TRV734 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV734 125 mg
Study: 31286645
Drug: TRV734 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV734 125 mg (drug in capsule after high-fat meal)
Study: 31286645
Drug: TRV734 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV734 (various doses 2 to 250 mg)
Study: 31286645
Drug: TRV734 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRV734 (various doses)
Study: 31596672
Drug: Type IV
Normalized name: Collagen type IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type IV recurrence (any combination of Types I-III, or multiple recurrences within a single Type)
Study: 26151924
Drug: DHA (1470
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (1470 mg/day) + EPA (147 mg/day)
Study: 23541756
Drug: ISIS 333611
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 333611 (0.15 mg, 0.50 mg, 1.50 mg, 3.00 mg)
Study: 16573261
Drug: 1% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% metronidazole cream
Study: 16573261
Drug: metronidazole creams
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metronidazole creams
Study: 6214216
Drug: Cleansing agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing agent without abrasive granules
Study: 29206921
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg modafinil
Study: 29206921
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg methylphenidate
Study: 29206921
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg 3,4‐methylenedioxymethamphetamine
Study: 26374918
Drug: Traditional diuretic
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional diuretic therapy
Study: 23349882
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta (IFNB) treatment
Study: 21592048
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg RSG XR
Study: 21592048
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg RSG XR
Study: 12840087
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autologous peripheral-blood hematopoietic progenitor-cell transplantation (6 g of cyclophosphamide, 480 mg of thiotepa, 1600 mg of carboplatin)
Study: 12840087
Drug: Conventional-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose chemotherapy (FEC every three weeks for five courses)
Study: 12840087
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy in patients with 10 or more positive nodes
Study: 12840087
Drug: Conventional-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose chemotherapy in patients with 10 or more positive nodes
Study: 11043056
Drug: Leflunomide (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide (loading dose of 100 mg orally for three days, followed by 20 mg daily)
Study: 11043056
Drug: Methotrexate or
Normalized name: methotrexate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate or sulphasalazine (previous treatments)
Study: 2069245
Drug: Epidural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural pethidine 25 mg in normal saline
Study: 27633651
Drug: Multigrowth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multigrowth factor (MGF) cream
Study: 21919966
Drug: Iloprost administered
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost administered for seven days after transplantation
Study: 21919966
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iloprost treatment)
Study: 19180065
Drug: Usual lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual lifestyle treatment program
Study: 19180065
Drug: Standard lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lifestyle treatment program
Study: 19180065
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle treatment program
Study: 17728363
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) (1.5-2.0 g/day)
Study: 17728363
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CTX) (0.75-1.0 g/m2)
Study: 15678245
Drug: ANP (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP (60 pmol/100 mL FAV/min)
Study: 15678245
Drug: Short-term infusions
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term infusions of ANP
Study: 15678245
Drug: Long-term infusions
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term infusions of ANP
Study: 15678245
Drug: Co-infusion of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-infusion of ANP, BNP, and CNP
Study: 10037839
Drug: hANP administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: hANP administered after operation until leaving ICU
Study: 10037839
Drug: No hANP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No hANP administered (Control)
Study: 7619666
Drug: Oral dextromethorphan
Normalized name: dextromethorphan Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextromethorphan 30 mg
Study: 7619666
Drug: Inhaled dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled dextromethorphan (1, 3, and 30 mg)
Study: 7619666
Drug: Oral matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral matched placebo
Study: 7619666
Drug: Matched inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched inhaled placebo
Study: 2244080
Drug: Flexible group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible group sequential testing using a Lan and DeMets procedure with permutation test
Study: 28327453
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation plus active oxybutynin administration
Study: 28327453
Drug: Active oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oxybutynin administration
Study: 19419331
Drug: Standard caspofungin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard caspofungin regimen (50 mg/day after a 70 mg dose on day 1)
Study: 19419331
Drug: High-dose caspofungin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caspofungin regimen (150 mg/day)
Study: 19419331
Drug: High-dose caspofungin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose caspofungin regimen
Study: 15496641
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg subcutaneously twice weekly) plus Methotrexate (weekly oral dose, median 20 mg)
Study: 11778664
Drug: 2,3-dimercapto-1-propanesulfonate 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,3-dimercapto-1-propanesulfonate 100-mg capsules 4 times a day for 1 week, repeated in the 3rd, 5th, and 7th week
Study: 11778664
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules resembling 2,3-dimercapto-1-propanesulfonate
Study: 9102259
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for colon carcinoma
Study: 9102259
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for rectal carcinoma
Study: 22278627
Drug: Daily dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dialysis for 1 week after standard hemodialysis (HD) for 1 week
Study: 22278627
Drug: Standard hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hemodialysis (HD) for 1 week after daily dialysis for 1 week
Study: 15667660
Drug: Doxycycline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (10 and 100 microg/ml) - ex-vivo treatment
Study: 7594338
Drug: Lansoprazole (LPZ)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LPZ) 30 mg q.d. for 8 weeks in GU and 6 weeks in DU
Study: 7594338
Drug: Roxatidine (R)
Normalized name: ROXATIDINE
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine (R) 75 mg b.i.d. for 8 weeks in GU and 6 weeks in DU
Study: 6107452
Drug: oxprenolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxprenolol, 40 mg three times a day
Study: 6107452
Drug: disopyramide phosphate,
Normalized name: Disopyramide Phosphate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: disopyramide phosphate, 150 mg three times a day
Study: 6306388
Drug: HCTZ 50
Normalized name: HCTZ 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 50 mg/day
Study: 6306388
Drug: MK-421 10
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-421 10 mg/day
Study: 6306388
Drug: HCTZ 50
Normalized name: HCTZ 50 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 50 mg/day plus MK-421 10 mg/day
Study: 31185057
Drug: Park Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Park Prescription intervention including face-to-face counseling and weekly structured exercise sessions in the park.
Study: 27711083
Drug: WBRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT plus vandetanib (100 mg once daily for 3 weeks)
Study: 17652648
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg per kilogram of body weight)
Study: 12387530
Drug: Home-made oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-made oral supplement (group A)
Study: 12387530
Drug: Home-made oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-made oral supplement (group B)
Study: 10460068
Drug: Initial intravenous
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial intravenous dose of 50 mg ranitidine; followed by either repeated injections (50 mg every 6 hours) or a continuous infusion (50 mg plus 0.125 mg/kg/h)
Study: 8528053
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose groups
Study: 2192011
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b (1.5 x 10(6) IU) injected intralesionally plus podophyllin resin applied topically once weekly for 3 weeks
Study: 31856760
Drug: Naloxone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.05 μg·kg−1·h−1)
Study: 21593283
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of celiprolol (100 mg)
Study: 21593283
Drug: Microdose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose of celiprolol (97.5 µg)
Study: 18073779
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g per day PS-enriched spread
Study: 17581778
Drug: Beta-blocker treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker treatment withdrawn
Study: 17581778
Drug: Beta-blocker dose
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker dose reduction
Study: 17581778
Drug: Beta-blocker maintained
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker maintained on the same dose
Study: 15037890
Drug: Latanoprost/timolol maleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost/timolol maleate fixed combination (LTFC) given once daily
Study: 15037890
Drug: Brimonidine twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine twice daily and latanoprost once daily
Study: 11418458
Drug: VBMCP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VBMCP with high-dose cyclophosphamide
Study: 11418458
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (VBMCP with interferon, high-dose cyclophosphamide, or VBMCP alone)
Study: 9249104
Drug: Midazolam premedication
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam premedication (0.04 mg/kg)
Study: 3541714
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of caffeine in solution orally
Study: 26756554
Drug: 15 intra-detrusor
Normalized name: somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 intra-detrusor injections of Dysport 750 U
Study: 26756554
Drug: 30 intra-detrusor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 intra-detrusor injections of Dysport 750 U
Study: 26756554
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 15 injections
Study: 26756554
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 30 injections
Study: 26756554
Drug: Dysport groups
Normalized name: Dysport
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport groups (both 15 and 30 injections)
Study: 19735512
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration HA fillers (24 mg/mL) - Juvéderm Ultra, Ultra Plus, and 30
Study: 19735512
Drug: Low concentration
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentration HA fillers (5.5 mg/mL) - Hylaform, Hylaform Plus, and Captique
Study: 11453908
Drug: Dithranol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol 2% cream + Clobetasol-17-propionate 0.05% ointment
Study: 11453908
Drug: Dithranol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dithranol 2% cream + Vehicle
Study: 1417691
Drug: Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive and behavioral treatments
Study: 31177856
Drug: Fremanezumab (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fremanezumab (subcutaneous injection, IgG2Δa)
Study: 27348908
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at acupoints on the axillary nerve distribution (Jianjing, Jianzhen, Jianliao, Jianyu, Quyuan, Tianzong, and trigger points in the scapular region) with Hegu needling and electric stimulation (continuous wave, 1Hz) for 30 min, once every two days for 10 treatments.
Study: 27348908
Drug: Regular acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular acupuncture at Dazhui, Tianzhu, Houxi, and cervical Jiaji (EX-B 2) with electric stimulation at cervical Jiaji (EX-B 2) for 30 min, once every two days for 10 treatments.
Study: 25019969
Drug: Split-dose sodium
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose sodium picosulfate plus magnesium citrate (PMC)
Study: 25019969
Drug: Standard-dose sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose sodium picosulfate plus magnesium citrate (PMC)
Study: 17980364
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and orlistat (120 mg, 3 times per day) for 24 weeks
Study: 12114416
Drug: SAM486A at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM486A at a maximum tolerated dose (MTD) of 102.4 mg/m2/day
Study: 10399774
Drug: 0.05 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/day of 17 beta-estradiol via skin patch
Study: 1574968
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion 1 mg kg‐1 h‐1 preceded by a 1 mg kg‐1 bolus
Study: 1574968
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 micrograms kg‐1 and diazepam 0.05 mg kg‐1
Study: 4028905
Drug: Ethanol 0.4
Normalized name: ethanol 0.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.4 g/kg body weight
Study: 4028905
Drug: Ethanol 0.6
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.6 g/kg body weight
Study: 4028905
Drug: Ethanol 0.8
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 0.8 g/kg body weight
Study: 26786710
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid plus subcutaneous injections of carbon dioxide
Study: 19049337
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg/d for 12 months after teriparatide)
Study: 19049337
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (after teriparatide)
Study: 17097942
Drug: Celsior solution
Normalized name: Fraxinus excelsior leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celsior solution (CS), n = 40
Study: 17097942
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin solution (UW), n = 40
Study: 9417503
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite in combination with intensive decongestive physical therapy
Study: 8256080
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg propranolol
Study: 8256080
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg atenolol
Study: 29555665
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet with 2300 mg Na
Study: 2187668
Drug: Urokinase administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase administered intravenously as a bolus before hospital admission (group I, n = 40)
Study: 2187668
Drug: Urokinase administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase administered intravenously as a bolus after hospital admission (group II, n = 38)
Study: 25765536
Drug: Topical tryptophan
Normalized name: Tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tryptophan
Study: 21246077
Drug: Sandblasted, silica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasted, silica coating via sol‐gel process prepared using 20 wt% silica sols, and then silane coupling agent applied (Group Al20C)
Study: 21246077
Drug: Sandblasted, silica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasted, silica coating via sol‐gel process prepared using 30 wt% silica sols, and then silane coupling agent applied (Group Al30C)
Study: 21246077
Drug: Sandblasted, silica
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasted, silica coating via sol‐gel process prepared using 40 wt% silica sols, and then silane coupling agent applied (Group Al40C)
Study: 21246077
Drug: Sandblasted +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasted + silane coupling agent applied (Group AlC)
Study: 17605780
Drug: Dexamethasone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (5 mg, n = 43) every six hours for a total of four doses on the day preceding extubation
Study: 17605780
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline, n = 43) every six hours for a total of four doses on the day preceding extubation
Study: 17605780
Drug: Dexamethasone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (5 mg, n = 43)
Study: 11795455
Drug: 4-aminopyridine (4-AP)
Normalized name: 4-AP
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP) 32 mg per day for 6 months
Study: 7986245
Drug: Folsan tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folsan tablet (5 mg folic acid)
Study: 7986245
Drug: Folsan injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folsan injection solution (reference preparation B)
Study: 2645385
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: discontinue therapy
Study: 2645385
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: reinduction for 4 weeks, then discontinue therapy
Study: 2645385
Drug: Regimen C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C: continue maintenance therapy for 2 more years, then discontinue
Study: 2645385
Drug: Boys randomized
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boys randomized to discontinue therapy